PORTFOLIO NEWS Ribon Therapeutics Raises $65 Million to Advance Pipeline of Novel Therapeutics Targeting Cellular Stress Pathways for Cancer January 4, 2019 Read More » Constellation Pharmaceuticals Provides Update on MANIFEST Clinical Trial of CPI-0610 in Myelofibrosis, Reviews 2018 Accomplishments, and Announces 2019 Data Disclosure Plans for Lead Programs January 3, 2019 Read More » Merck Exercises Option for NGM Bio’s Investigational Insulin Sensitizer, NGM313, for the Treatment of NASH and Type 2 Diabetes January 3, 2019 Read More » Gritstone Oncology Announces FDA Fast Track Designation for GRANITE-001 for the Treatment of Colorectal Cancer December 20, 2018 Read More » Carmot Therapeutics Initiates Phase 1 Trial to Treat Type 2 Diabetes December 19, 2018 Read More » Gritstone Oncology Announces Publication in Nature Biotechnology of Neoantigen Identification Capabilities of its Artificial Intelligence Platform, EDGE™ December 17, 2018 Read More » Gritstone Oncology Advances Solid Tumor Bispecific Antibody Program into Lead Optimization Phase; Appoints Vice President of Antibody Therapeutics to Spearhead December 10, 2018 Read More » Constellation Pharmaceuticals Initiates Phase 2 Portion of ProSTAR Clinical Trial in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) December 10, 2018 Read More » Kallyope Inc. Announces $21 Million Expansion of Series B Financing December 5, 2018 Read More » Constellation Pharmaceuticals Appoints Patrick Trojer, Ph.D., as Chief Scientific Officer November 29, 2018 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
Ribon Therapeutics Raises $65 Million to Advance Pipeline of Novel Therapeutics Targeting Cellular Stress Pathways for Cancer January 4, 2019 Read More »
Constellation Pharmaceuticals Provides Update on MANIFEST Clinical Trial of CPI-0610 in Myelofibrosis, Reviews 2018 Accomplishments, and Announces 2019 Data Disclosure Plans for Lead Programs January 3, 2019 Read More »
Merck Exercises Option for NGM Bio’s Investigational Insulin Sensitizer, NGM313, for the Treatment of NASH and Type 2 Diabetes January 3, 2019 Read More »
Gritstone Oncology Announces FDA Fast Track Designation for GRANITE-001 for the Treatment of Colorectal Cancer December 20, 2018 Read More »
Gritstone Oncology Announces Publication in Nature Biotechnology of Neoantigen Identification Capabilities of its Artificial Intelligence Platform, EDGE™ December 17, 2018 Read More »
Gritstone Oncology Advances Solid Tumor Bispecific Antibody Program into Lead Optimization Phase; Appoints Vice President of Antibody Therapeutics to Spearhead December 10, 2018 Read More »
Constellation Pharmaceuticals Initiates Phase 2 Portion of ProSTAR Clinical Trial in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) December 10, 2018 Read More »
Constellation Pharmaceuticals Appoints Patrick Trojer, Ph.D., as Chief Scientific Officer November 29, 2018 Read More »
